Benevir has been accepted into the Hive program and will be taking part in the TEDMED 2014 convention from September 10-12, 2014 in Washington, DC and San Francisco.
BeneVir’s cancer therapeutic is designed to induce the immune system to recognize and rid the body of two types of tumor cell. The first type is responsive to current immunotherapies, and many patients experience complete remissions. Tumor cells of the second type have evolved to hide from the immune system and are refractory to current immunotherapies. These tumor cells are ultimately responsible for tumor recurrence and poor clinical outcomes. To our knowledge, there is no technology in development that can induce immunity to both types of tumor cell. We feel we have a unique perspective in the emerging field of cancer immunotherapy and that our technology will exhibit enhanced clinical benefit for a wide range of cancer patients.
Read the full interview after the jump!
Healthcare startups, and all startups for that matter, need investors and funding to stay alive. For this reason, MedCity is pleased to announce that investor Andrew Jay, MD, will be speaking at CONVERGE. Dr. Jay is the head of the medical solutions fund at HealthCare Fund at Siemens Venture Capital, which invests in companies focusing on imaging, diagnostics and health IT.
Jay will be speaking on the second day of MedCity CONVERGE at 9:20 a.m. The third annual CONVERGE is July 15-16 in Philadelphia.
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced the launch of a new service offering: the Startup Package for Client Companies. The new package is designed to provide early-stage biohealth companies in Central Maryland with access to critical professional services – including corporate legal guidance, intellectual property, banking, accounting, payer and strategy, and grant support – as an enhanced benefit to working with BHI.
“We are proud to offer this service to our startup clients seeking to commercialize biohealth products,” said Richard Bendis, President & CEO. “BHI aims to facilitate the development of commercially viable health-related products and companies. Providing access to these professional services is a critical step towards helping our biohealth startup clients in achieving this goal.”
BHI has partnered with a supporting network of professional service providers that share the same vision for growing Maryland’s biohealth sector, including Venable LLP, M&T Bank, Aronson, Miles & Stockbridge, InHouse Patent Counsel, Science Sherpa, Center for Medical Technology Policy, ADVI, and BBC Entrepreneurial Training & Consulting. These firms understand the nature and needs of startup companies, and offer preferred rates for client companies.
One of the under-appreciated features of the San Diego innovation ecosystem is the increasing significance of its proximity to one of North America’s most dynamic manufacturing hubs, Baja California, and in particular, Tijuana.
In 2006 my research team at UC San Diego published a bilingual report on the potential synergies between the innovation economy on the U.S. side of the border and the increasing manufacturing capabilities, engineering, and technical skills on the Mexican side. The cluster of manufacturing expertise includes companies in Tijuana that specialize in producing medical devices, pharmaceuticals, and electronics.
MIMETAS is part of Medical Delta: the consortium of top life sciences and medical technology partners in the Netherlands. Medical Delta is a research, sales and logistics driven life sciences and medical technology cluster situated in the economic heart of the Netherlands, between Amsterdam Schiphol Airport and the Port of Rotterdam. In this Leiden — Delft — Rotterdam region, top-ranked universities and medical centers work together with industry and government to provide a dynamic environment for innovative spinoffs and international companies. With thanks to Roel Kamerling.
Richard Bendis and BioHealth Innovation were among the small businesses and individuals honored by the US Small Business Administration at the 2014 Tibbetts awards. Winners of the award have been critical in supporting the SBIR/STTR program in many different ways and are at the forefront of driving innovation. Read the full PR Newswire press release here.
The BHI SBIR/STTR Federal Funding Assistance Program offers biohealth companies support in preparing applications for federal funding inclusive of SBIRs, STTRs, and other federal government awards. Companies submit their federal funding concepts and receive pre-proposal feedback to help troubleshoot and strengthen your application. Further support from professional consultants and service providers is available to assist in improving your application.
For more information on the program, contact Ethan Byler.
BHI is pleased to announce the promotion of Amanda Wilson to the position of Director, Finance & Human Resources. Amanda joined BioHealth Innovation, Inc. two years ago as the Operations Manager.
Over the past two years, Amanda has transitioned BHI’s accounting method from cash to accrual. She has ensured BHI compliance with Generally Accepted Accounting Principles (GAAP), and has represented BHI through two successful audits. In addition, Amanda has developed human resources policies and procedures and has maintained employee access to BHI’s benefits package. Amanda recently completed her MBA at The George Washington University, and is able to augment her pre-existing skills through this degree.
Join us in congratulating Amanda on a well-deserved promotion!